Philippe RenaudPhilippe Renaud is Professor at the Microsystem Laboratory (LMIS4) at EPFL. He is also the scientific director of the EPFL Center of MicroNanoTechnology (CMI). His main research area is related to micronano technologies in biomedical applications (BioMEMS) with emphasis on cell-chips, nanofluidics and bioelectronics. Ph. Renaud is invloved in many scientifics papers in his research area. He received his diploma in physics from the University of Neuchâtel (1983) and his Ph.D. degree from the University of Lausanne (1988). He was postdoctoral fellow at University of California, Berkeley (1988-89) and then at the IBM Zürich Research Laboratory in Switzerland (1990-91). In 1992, he joined the Sensors and Actuators group of the Swiss Center for Electronics and Microtechnology (CSEM) at Neuchâtel, Switzerland. He was appointed assistant professor at EPFL in 1994 and full professor in 1997. In summer 1996, he was visiting professor at the Tohoku University, Japan. Ph. Renaud is active in several scientific committee (scientific journals, international conferences, scientific advisory boards of companies, PhD thesis committee). He is also co-founder of the Nanotech-Montreux conference. Ph. Renaud is committed to valorization of basic research through his involvement in several high-tech start-up companies.
Nikolaos StergiopoulosEducation
MTE, Managing the Technology Enterprise Program (2000), IMD, Lausanne
Ph.D. in Biomedical Engineering & Engineering Mechanics (1990) Iowa State University, Ames, Iowa.
MS in Biomedical Engineering (1987) Iowa State University, Ames, Iowa.
Diploma in Mechanical Engineering (1985) National Technical University of Athens.
Professional Activities
2002 - present: Professor and director of LHTC
2010 - present: Founder and director of Rheon Medical SA, Préverenges, Switzerland
2008 - present: Founder and director of Antlia S.A., PSE-C, EPFL campus, Switzerland
1998 - 2007: Founder and Scientific Director of EndoArt S.A., Lausanne, Switzerland
1996 - 2002: Assistant professor at the Biomedical Engineering Laboratory, Swiss Federal Institute of Technology, Lausanne, Switzerland.
1991 - 1996: Research Associate at Swiss Federal Institute of Technology - Lausanne
1990 - 1991: Lecturer, Iowa State University
Florian Maria WurmFlorian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
